| Title |
Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists’ arsenal
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, May 2015
|
| DOI | 10.2147/tcrm.s82049 |
| Pubmed ID | |
| Authors |
Panagiota Papanagnou, Panagiotis Baltopoulos, Maria Tsironi |
| Abstract |
Experimental data indicate that several pharmacological agents that have long been used for the management of various diseases unrelated to cancer exhibit profound in vitro and in vivo anticancer activity. This is of major clinical importance, since it would possibly aid in reassessing the therapeutic use of currently used agents for which clinicians already have experience. Further, this would obviate the time-consuming process required for the development and the approval of novel antineoplastic drugs. Herein, both pre-clinical and clinical data concerning the antineoplastic function of distinct commercially available pharmacological agents that are not currently used in the field of oncology, ie, nonsteroidal anti-inflammatory drugs, antihypertensive agents, and anti-human immunodeficiency virus agents inhibiting viral protease, are reviewed. The aim is to provide integrated information regarding not only the molecular basis of the antitumor function of these agents but also the applicability of the reevaluation of their therapeutic range in the clinical setting. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Unknown | 58 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 19% |
| Student > Bachelor | 10 | 17% |
| Researcher | 8 | 14% |
| Student > Ph. D. Student | 5 | 8% |
| Unspecified | 4 | 7% |
| Other | 11 | 19% |
| Unknown | 10 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 39% |
| Biochemistry, Genetics and Molecular Biology | 4 | 7% |
| Nursing and Health Professions | 4 | 7% |
| Unspecified | 4 | 7% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 11 | 19% |
| Unknown | 11 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 May 2015.
All research outputs
#16,721,208
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#809
of 1,323 outputs
Outputs of similar age
#159,715
of 278,920 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#27
of 42 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,920 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.